A Study to Explore the Efficacy of JNJ-67953964 in the Treatment of Depression
Status:
Completed
Trial end date:
2020-05-06
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy of JNJ-67953964 compared to placebo
when administered as adjunctive treatment in participants with Major Depressive Disorder
(MDD) partially responsive to selective serotonin reuptake inhibitor/
serotonin-norepinephrine reuptake inhibitor (SSRI/SNRI) treatment in terms of reduction of
symptoms of depression, as assessed by the change from baseline on the Montgomery Asberg
Depression Rating Scale (MADRS) in non-responders during the placebo lead-in period.